Oana Cristina Costescu, Eugen Radu Boia, Marioara Boia, Daniela Mariana Cioboata, Florina Marinela Doandes, Nicoleta Lungu, Mihai Dinu, Emil Radu Iacob, Aniko Maria Manea
Recombinant human erythropoietin (rhEPO) treatment is an alternative to red blood cell (RBC) transfusions in neonates presenting anemia of prematurity (AOP). This study assesses the impact of early rhEPO administration on AOP (any stage) incidence, as well as the incidence of individual AOP stages and RBC transfusions. Out of 108 preterm neonates, 49 were administered rhEPO and compared to the remaining group using univariate and multivariate analyses. Univariately, gestational age (GA), birth weight (BW), hemoglobin (Hb), hematocrit (HCT), RBC levels, and iron administration were significantly associated with AOP ( p < 0...
November 24, 2023: Children